The exophthalmos treatment market is at around USD 271.8 million in 2025 and around USD 318.2 million in 2035 with a CAGR of 8.1% during 2025 to 2035. The exophthalmos treatment market growth is unmatched during 2025 to 2035 with the high prevalence of thyroid eye disease (TED), advancements in treatments through surgeries and non-surgeries, and enhanced awareness of the importance of early diagnosis.
Some of the forces driving change in the treatment market for exophthalmos include a global prevalence of autoimmune diseases such as Graves' disease, and the primary force driving thyroid-associated exophthalmos. More medical treatment with agents of biologic therapy such as teprotumumab has changed therapy by targeted therapy with less side effect than traditional corticosteroids and radiation treatment.
With this, unaffordability and unavailability in certain geographies remain a major driving factor of the growth of the market. Due to this, organizations are shifting toward the manufacturing of cost-reducing therapeutic products while providing enhanced patient outcomes.
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 271.8 million |
| Industry Value (2035F) | USD 318.2 million |
| CAGR (2025 to 2035) | 8.1% |
The market has been segmented based on the mode of treatment, i.e., biologic therapies, surgery, and corticosteroid therapy. Biologic drugs such as monoclonal antibodies are highly trendy as they are capable of targeting specific pathways that lead to inflammation. Surgery such as decompression surgery of the orbit, though still, can in fact be categorized under treatment of extreme loss of vision.
Corticosteroids, though still the standard, are being gradually substituted by even better and targeted forms because of side effect-related complications in the long term. The following treatments including radiation therapy, artificial tears, and behavioural modification need to remain important in the small and medium degree loss conditions.
Explore FMI!
Book a free demo
The highest market expansion in the market for exophthalmos treatment is in North America due to the high incidence growth rate for thyroid eye disease as well as high growth of high-tech adoption of biologic drugs.
America, and the USA in particular, has seen rapid-pace uptake of FDA-approved drugs like teprotumumab that place non-surgical treatment on a new pedestal. Expenditure on R&D of emerging treatment techniques like gene therapy and stem cell-based therapy is also driving market growth in the region. Additionally, the presence of cutting-edge health infrastructure as well as rising campaigns on time-bound diagnosis are also contributing to a good market situation.
Europe also possesses a stronger market share, and leading nations like Germany, the UK, and France are experiencing huge demand for exophthalmos advanced treatment. The area is also furnished with strong pharma industry, colossal research operations, and highly advanced healthcare infrastructure upon which patients are also able to avail the most recent treatments.
Expansion in clinical trials of new biologic pharma drugs and orbital reconstructive surgery also propel market growth further. Tough launch approval guidelines for new drugs and the reimbursement problem in some nations are hampering market growth, however.
Asia-Pacific is also plagued by the highest market growth for exophthalmos treatment with a growing number of thyroid diseases reported in China, India, and Japan. Investment in medicine and improved access to specialist ophthalmic care are the primary market drivers. Inadequate diagnosis and ignorance in rural areas are a drawback nonetheless.
Governments and hospitals operate information programs and screening processes to facilitate improved early diagnosis and access to therapy. Local manufacturers increasingly become involved in the production of biologics because there is greater demand for lower-cost alternatives of therapy.
Challenge
High Cost and Inaccessibility
Bulging eyes or exophthalmos is costly to treat, and it is difficult for most patients to afford. The use of biologic drugs like the monoclonal antibody drug teprotumumab has been found to cure the condition but at the cost of an extremely high price, which is not affordable by people residing in poor communities.
Not only are the drugs costly, but even the hospitals within the third-world nations cannot include such a price on the list of drugs so that the quantity of money which they require cannot be inserted into the patients. Also, lack of specialist eye physicians and surgeons in developing or rural regions is another massive blow.
This shortage of healthcare personnel will most likely lead to a delay in treatment and diagnosis time, thus exacerbating the condition further. The three obstacles of prohibitively expensive cost of care, gaps in coverage by insurance, and truncated access to care at referral facilities are impossible barriers to decent treatment of exophthalmos, particularly to poor individuals in the world.
Opportunity
Medical Technological Advances with Less Costly and Less Minimally Invasive Treatment
Medical technological advances will render treatment of exophthalmos prevalent and less costly. Affordable biosimilars to monoclonal antibodies are an economic viable option for those patients who simply are not able to afford the cost of biologic drugs, which are pricey. They are as good as the parent monoclonal antibodies but at very low prices, offering what would otherwise be an expensive method of treatment at a price that is affordable to nearly everyone.
In addition, targeted small-molecule drugs are being designed to treat the exophthalmos diseases more effectively, perhaps at lower cost of treatment and side effects. Minimally invasive decompression procedures are becoming more popular with the benefit of quicker recovery and fewer complications than conventional methods.
Diagnostic machinery with AI support help in speeding up and accurate diagnosis of exophthalmos to enable quicker treatment and improved treatment for the patient. Telemedicine has also helped with improved access to treatment, especially in rural areas, through online consultation for first-level diagnosis and then treatment of the disease.
Between 2020 and 2024, the market of exophthalmos treatment underwent exponential transformation mostly with the enhanced use of biologic drugs. Use and access to monoclonal antibody treatments such as Tepezza witnessed sweeping transformations away from conventional therapy in the form of radiation and corticosteroids.
The biologic drugs brought more, less side effect-profile non-surgical alternatives to the table, hence the trend under which the disease was treated. Apart from these developments, there was more emphasis on early diagnosis such that the early intervention enhanced the patient outcome. There was also more emphasis on personalized medicine, which also helped because the drugs and the therapy became more individualized for specific patients, thus becoming overall better and showing a more targeted type of treatment.
In coming years, 2025 to 2035, the market for the treatment of exophthalmos will be centered on making biologic therapy more accessible, surmounting the obstacles of cost and access. Artificial intelligence in diagnostic tests will allow for rapid and accurate diagnosis sooner, thus earlier intervention. Regenerative medicine and gene therapy are promising for the future, such as new, possibly curative therapies for exophthalmos.
These developments, accompanied by efforts made by state governments to make the cost of care lower, have the ability to transform the complexion of treatment altogether, providing enhanced patient outcomes throughout the globe.
Market Shifts: A Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Shift | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Regulatory agencies came to appreciate exophthalmos as a major health issue, prompting additional research funding and the development of therapies. |
| Technological Advancements | The advent of biologics, like Tepezza, provided patient-specific treatment choices for exophthalmos associated with thyroid eye disease. |
| Treatment Modalities | Corticosteroids and radiation were used with some success, and side effects. |
| Patient Awareness and Education | There was poor patient awareness with consequent delay in diagnosis and poor outcomes with treatment. |
| Healthcare Infrastructure | There were specialized care centers for exophthalmos in fewer numbers, where patients tended to be treated at general ophthalmology centers. |
| Research and Development | Early research dealt with pathophysiology of the exophthalmos condition and few clinical trials for emerging treatment. |
| Market Growth Drivers | The incidence of thyroid illness, especially of Graves' disease, has continued to grow and raise demand for exophthalmos treatments. |
| Market Shift | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Governments enact rigorous treatment regimens for the control of exophthalmos, protocolized care standards, and early diagnosis and intervention. |
| Technological Advancements | Advancements in highly sophisticated minimally invasive surgical techniques and customized medicine strategies enhance outcomes and effectiveness. |
| Treatment Modalities | Use of combination therapies, employing immunomodulators and biologics, results in safer and more effective therapy. |
| Patient Awareness and Education | Public health education and campaigns rise, with concomitant patient awareness, resulting in earlier detection and better control of exophthalmos. |
| Healthcare Infrastructure | Greater availability of specialist orbital disease clinics with multidisciplinary specialists enhances patient access to specialist services. |
| Research and Development | Too much R&D generates a robust pipeline of new therapies, including gene therapies and novel biologics, for improved treatments. |
| Market Growth Drivers | Technology advances, improved healthcare infrastructure, and rising patient awareness drive market growth, with focus on early intervention and personalized treatment strategies. |
Thyroid eye disease (TED) has increased continuously in the United States, and there has always been a demand for effective treatment for exophthalmos. Approval of Tepezza in 2020 was a milestone in TED treatment, specifically with an even more selective drug. Since this discovery, patients' outcomes have been improved, but other studies are continuously conducted to identify new treatments for even greater effectiveness.
Due to better awareness and an effective system of health care, the United States is far ahead of all other countries in developing new therapies. Therapeutic targeting and individualized therapy will definitely boost therapy innovation for the treatment of exophthalmos.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 8.1% |
Early diagnosis and increased awareness towards thyroid eye disease in the United Kingdom allowed for earlier treatment of exophthalmos. The National Health Service (NHS) also has standard treatment methods in place to treat good patients equally. The process is aimed at reducing delay in diagnosis and treatment of the patient and better results of the patient.
NHS and academy partnership also continues to work together on research into newer therapies. Improved quality of life of the patients and improving better and better treatment of exophthalmos patients is the goal.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 8.2% |
The European Union has invested substantial amounts of finances on research in unusual conditions such as thyroid eye disease (TED) in the hope of producing sophisticated types of therapy for exophthalmos. Trans-EU care partnerships among EU members have increased access to expert care, with patients receiving quality care throughout the EU.
Personalized medicine in the EU will be adding to even more personalized and effective therapy for exophthalmos. In addition, research studies and research grants continue to expand the volume of data on TED, increases that will be sure to fuel market expansion and improve patient outcomes in the future.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 8.0% |
There has been a growing population of age in Japan with consequent incidences of thyroid disease, thereby increasing the incidence of exophthalmos. The medical system of Japan emphasizes much on early treatment and diagnosis, which is a process that has been of immense help in better outcomes of patients.
Japan also boasts advanced surgery methods that have helped towards better prognostications for curing exophthalmos patients. Current clinical trials are even helping with the ongoing advancement of therapeutic methods available for the cure of the disorder. With a special focus on becoming more and more innovative as well as providing patients with improved treatments, Japan is becoming even more advanced at advancing the treatment of thyroid eye disease with hopes for even better treatment in the future.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 8.5% |
South Korea experienced an increase in the prevalence of exophthalmos, followed by investment in the country's health infrastructure to enable proper treatment of the disease. South Korea adopted new technologies like minimal invasive treatment to enhance therapy outcomes and recovery periods.
The technologies enhanced treatments and even lessened them in expense to patients. The health campaigns have also been instrumental in increasing awareness about exophthalmos, which has led to earlier medical evaluation and improved diagnostics. South Korea's rapid march towards healthcare and technology embracement theme is thus enhancing the standard of living of the exophthalmos patients.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 8.2% |
The non-surgical treatment segment leads the market for the management of exophthalmos since corticosteroids are best suited to treat inflammation and the diminution of swelling in the orbit. Prednisone and dexamethasone are the most frequently prescribed corticosteroids, which have been found to be highly effective in reducing proptosis and improving visual function in patients with thyroid eye disease. They are the most in-demand among doctors since they can provide relief immediately.
Monoclonal antibodies, especially teprotumumab, are now a coveted targeted therapy for moderate-to-severe exophthalmos. The biologic drug demonstrates unmatched efficacy through clinical trials by directly blocking the insulin-like growth factor-1 receptor (IGF-1R) pathway, eventually reducing proptosis and inflammation. Because of the extremely expensive nature of monoclonal antibody therapy, its predominance over recalcitrant cases to traditional treatments remains an impetus.
Radiotherapy is also an adjuvant therapy, specifically in corticosteroid or biologic failure. Low-dose radiotherapy of the orbit has also been used for managing inflammation and preventing disease progression. The increasing patient and physician resistance to surgery has also prompted increased growth in this segment.
Surgical treatment is reserved for the most severe exophthalmos with vision loss or cosmetic issues significantly affecting patient quality of life. Orbital decompression is still the treatment of choice in patients with compressive optic neuropathy. Endoscopic surgery is less invasive and has better results of surgery with quicker recovery and fewer postoperative complications.
Blepharoplasty is also an important part, specifically in patients of eyelid retraction secondary to thyroid-associated orbitopathy. Such operations as levator recession permit restoration of the lid position, and keratopathy secondary to exposure, and overall ocular comfort improves. Similarly, this has been in greater demand with more awareness of functional as well as cosmetic rehabilitation of the exophthalmos patient.
Strabismus combined with exophthalmos is treated mostly by eye muscle surgery. Fixation surgeries like adjustable sutures are used to enable proper positioning of the eyes and enable improvement in binocular vision. Increased growth in enhanced ophthalmic surgical techniques drives the growing demand for precision surgery further and thus the growth for the surgical treatment segment grows.
Hospital pharmacies enjoy a monopoly in the treatment market of exophthalmos since they are the first point of reference for dispensing prescription drugs, such as corticosteroids, monoclonal antibodies, and other drug therapies. Specialized ophthalmic treatment within hospitals guarantees prompt and sufficient treatment of patients, benefiting this segment's dominant position.
Specialty clinics are also experiencing tremendous growth due to growing numbers of specialty endocrinology and ophthalmology centers to address thyroid eye disease. Specialty clinics offer packaged treatment plans with a combination of surgical and medical treatments for the best patient outcomes. Growing demand for outpatient surgery and customized care is fueling growth in this segment.
The other categories like retail pharmacies and online drugstores are in higher demand since the patient needs prompt access to medications that have been prescribed. The e-pharmacy phenomenon, especially in matured markets, is going to shape the future delivery trends of the treatment of exophthalmos.
The exophthalmos treatment market is a highly competitive market with gigantic pharmaceuticals across the globe as well as local experts powering the quest for innovation in the methods of treatment. Certain market leaders possess large stakes in the market, driving innovations in therapies, biologics, and surgery.
The companies optimize the effectiveness of treatments, reduce side effects, and establish patient-friendly drug therapies. There are established pharma giants and emerging biotechs on the market, and they all contribute meaningfully to the best treatment options for exophthalmos.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Horizon Therapeutics | 15-20% |
| Novartis AG | 12-16% |
| Amgen Inc. | 10-14% |
| Viridian Therapeutics | 6-10% |
| Immunovant, Inc. | 4-8% |
| Other Companies (combined) | 40-50% |
| Company Name | Key Offerings/Activities |
|---|---|
| Horizon Therapeutics | Develops Tepezza, the first FDA-approved treatment for thyroid eye disease (TED). Focuses on expanding global reach and further indications. |
| Novartis AG | Conducts clinical trials on IGF-1R inhibitors for TED. Invests in ophthalmic research and strategic acquisitions. |
| Amgen Inc. | Engages in biologics targeting inflammatory pathways. Advances monoclonal antibody development for autoimmune-related eye disorders. |
| Viridian Therapeutics | Specializes in IGF-1R inhibitors as an alternative to Tepezza. Strengthens pipeline with innovative approaches for TED treatment. |
| Immunovant, Inc. | Focuses on FcRn inhibitors to reduce autoantibody-mediated eye inflammation. Expands research on autoimmune ophthalmic conditions. |
Key Company Insights
Horizon Therapeutics (15-20%)
Horizon Therapeutics leads exophthalmos therapy with Tepezza (teprotumumab-trbw), the only FDA-approved exophthalmos treatment for thyroid eye disease. Horizon is working diligently to develop Tepezza's footprint outside the USA, presently served in European and Asian territories. Ongoing R&D of more indications and second-generation biologics keeps Horizon ahead in this specialty therapeutic market.
Novartis AG (12-16%)
Novartis AG takes the lead in exophthalmos treatment discovery in novel biologics and IGF-1R inhibitors pipeline. It has its ophthalmology business making strategic deals to develop therapeutic portfolios. Novartis is taking advantage of its global presence to introduce innovative therapeutics to emerging as well as mature markets.
Amgen Inc. (10-14%)
Amgen Inc. is a biologics giant with a concentrated interest in autoimmune and inflammatory disease, including exophthalmos. It is developing monoclonal antibodies to block central inflammatory pathways in thyroid eye disease. Its strategic partnerships with biotech companies augment its leverage in this specialty space.
Viridian Therapeutics (6-10%)
Viridian Therapeutics is a nascent biotech company working to develop IGF-1R inhibitors as a Tepezza alternative that is more affordable but just as effective. The company is progressing at breakneck speed with clinical trials, set to be at the leading edge in the industry for TED treatment in the future.
Immunovant, Inc. (4-8%)
Immunovant, Inc. is targeting FcRn inhibitors for the treatment of autoimmune-mediated inflammation leading to exophthalmos. It maintains its pipeline of candidate drugs against the diminishment of autoantibody activity in TED patients. Immunovant is investing directly in its ophthalmic franchise outside of TED.
Other Key Players (40-50% Combined)
Beyond these dominant players, several companies collectively hold a significant market share, contributing to treatment innovations, affordability, and patient access. These include:
The overall market size for exophthalmos treatment market was USD 271.8 million in 2025.
The exophthalmos treatment market is expected to reach USD 318.2 million in 2035.
The increasing prevalence of thyroid eye disease, advancements in treatment options, and rising awareness about ophthalmic conditions are expected to drive the exophthalmos treatment market during the forecast period.
The top 5 countries which drive the development of the exophthalmos treatment market are the USA, Germany, the UK, China, and Japan.
On the basis of treatment type, corticosteroid therapy is expected to command a significant share over the forecast period.
Gastro-retentive Drug Delivery Systems Market - Trends & Demand 2025 to 2035
Healthcare Biometrics Market Trends - Growth, Demand & Forecast 2025 to 2035
Healthcare API Market Growth – Trends & Forecast 2025 to 2035
Gastrointestinal Stent Market Growth – Trends & Forecast 2025 to 2035
Gel Implants Market Analysis - Trends, Share & Forecast 2025 to 2035
3D Printing Dental Devices Market Growth - Trends & Forecast 2025 to 2035
Exophthalmos Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
